During the past decade, Hematology-Oncology Associates of NNJ, P.A. conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 11 clinical trials were completed, i.e. on average, 366.7% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 3 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hematology-Oncology Associates of NNJ, P.A." #1 sponsor was "Celgene" with 5 trials, followed by "US Oncology Research" with 4 trials sponsored, "Amgen" with 2 trials sponsored, "Novartis Pharmaceuticals" with 2 trials sponsored and "Accelerated Community Oncology Research Network" with 2 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hematology-Oncology Associates of NNJ, P.A." #1 collaborator was "Sanofi" with 2 trials as a collaborator, "Amgen" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "Celgene" with 1 trials as a collaborator and "Eli Lilly and Company" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Hematology-Oncology Associates of NNJ, P.A." are "Breast Cancer" (3 trials), "Multiple Myeloma" (3 trials), "Advanced Breast Cancer" (1 trials), "Advanced Prostate Cancer" (1 trials) and "Androgen-independent Prostate Cancer" (1 trials). Many other conditions were trialed in "Hematology-Oncology Associates of NNJ, P.A." in a lesser frequency.

Most popular intervention types in "Hematology-Oncology Associates of NNJ, P.A." are "Drug" (17 trials), "Biological" (2 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Bortezomib" (2 trials), "Dexamethasone" (2 trials), "Docetaxel" (2 trials) and "Lenalidomide" (2 trials). Other intervention names were less common.

The vast majority of trials in "Hematology-Oncology Associates of NNJ, P.A." are 13 trials for "All" genders, 3 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Hematology-Oncology Associates of NNJ, P.A.". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in Hematology-Oncology Associates of NNJ, P.A., undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Hematology-Oncology Associates of NNJ, P.A., 1 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".